about
Organ allocation for chronic liver disease: model for end-stage liver disease and beyondDiagnostic accuracy of magnetic resonance elastography in liver transplant recipients: A pooled analysisUnderestimation of liver-related mortality in the United States.Impact of the center on graft failure after liver transplantationLack of association between hepatitis C infection and chronic kidney diseaseUse of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysisDevelopment of organ-specific donor risk indices.Model for end-stage liver disease: end of the first decade.Daclizumab induction therapy in liver transplant recipients with renal insufficiencyLiver stiffness is associated with risk of decompensation, liver cancer, and death in patients with chronic liver diseases: a systematic review and meta-analysis.Role of magnetic resonance elastography in compensated and decompensated liver disease.Natural history of cirrhosis.Epidemiology, diagnosis and early patient management of esophagogastric hemorrhage.Model for end-stage liver disease score and MELD exceptions: 15 years later.Incorporation of Noninvasive Measures of Liver Fibrosis Into Clinical Practice: Diagnosis and Prognosis.Non-invasive assessment of liver fibrosis and prognosis.The donor risk index: A decade of experience.Impact of birth cohort screening for hepatitis C.Early outpatient follow-up and 30-day outcomes in patients hospitalized with cirrhosis.Rational Heart Transplant From a Hepatitis C Donor: New Antiviral Weapons Conquer the Trojan Horse.Hospitalization for underage drinkers in the United States.Liver transplantation for nonalcoholic steatohepatitis.Prediction of early mortality after variceal bleeding: score one more for MELD.Extracorporeal Cellular Therapy (ELAD) in Severe Alcoholic Hepatitis - A Multinational, Prospective, Controlled, Randomized Trial.Patient Reported Outcomes in Cirrhosis: A Scoping Review of the Literature.The Living Donor Collective: A Scientific Registry for Living Donors.Artificial neural networks and liver transplantation: Are we ready for self-driving cars?ACR Appropriateness Criteria® Chronic Liver Disease.ACR Appropriateness Criteria® Chronic Liver Disease.Recipient characteristics and morbidity and mortality after liver transplantation.Predicting renal recovery after liver transplant with severe pretransplant subacute kidney injury: The impact of warm ischemia time.De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial.Fibrolamellar hepatocellular carcinoma presenting with Budd-Chiari syndrome, right atrial thrombus, and pulmonary emboli.Elastography in Overweight and Obese Patients With Chronic Liver Disease.Can one pill a day keep rejection away?Acute-on-Chronic Liver Failure.Acute-on-chronic liver failure.A model for Glomerular filtration Rate Assessment In Liver disease (GRAIL) in the presence of renal dysfunctionPredictors of outcomes in patients with ascites, hyponatremia, and renal failure.Noninvasive diagnosis of liver fibrosis in adults.
P50
Q24633350-98F65035-F4C8-42FD-90FF-3376865C746CQ30374016-37ACF28B-A888-4684-91F1-08826A3620D2Q30564165-6CCD5CA2-EC8C-467D-BC3F-48CA54B109ABQ34034827-0BE6E459-50D9-4BF6-8F7A-421C58187A1BQ34034846-45EE0449-3A98-4406-A638-9156E5F613C2Q34034891-CE62BA24-9A93-4A7D-A1B6-D2F0BECD7FD7Q35903771-9C168C75-95CE-46CF-8011-B4F1B3E0F38BQ36588122-798C5E7F-BC1C-49C1-B5F5-913ED21B617AQ36710213-B8C9C604-3AD9-4B9C-A8F3-C3202C213ACCQ37511482-4B0AC01C-E4D6-4C73-A6DE-2D103088E0A7Q37716891-697F9E18-5CFA-4C8C-BA87-AEB6D00DA945Q38073661-347C32D9-2BF8-4EFA-B6B9-7AD8AD7AAAAFQ38273941-340CCFE3-C18B-4BF4-A96B-A3B863904ACFQ38504284-585C4ACA-4291-42AB-852D-852AF3399975Q38557475-2BC1F0DC-AB15-46F1-933C-68FC146B4209Q38588078-4C73898F-7EE5-4EDD-BD6A-77DC0BB6821BQ38738555-2F365421-E722-4803-B8E7-393241BAA7E3Q39238840-2088C5E1-EBB5-405B-9F60-233412F43F3CQ39908463-1ED79B38-498D-416D-9683-71A21D537241Q40085730-6A5D2235-DB08-42D5-B2EC-65E10B63CFC9Q43669288-9C59B855-94D4-4E15-B82E-C0E0098DBC8BQ44069322-7258C214-9373-4491-80CF-E781F0546013Q44916289-07F138FE-43F7-4DD2-8753-9F7757CAE94CQ46670808-3755BBC8-BFEB-4B75-80E3-F35DD2E37D61Q47561441-240B85D1-72F2-4444-B97C-E479CE60816CQ48126975-6A78B7F5-D843-435A-A7BE-6514F966155EQ48166676-4498FA86-9B50-4560-B0C9-CE1E6C1B6926Q48561940-97B92E60-70BE-4B26-84EF-81F46E2B3ACDQ48655137-721D1505-1048-4050-AC9A-4CE88F15F893Q49904203-2EB10062-2F4A-485A-9534-13C9139890FFQ53080815-32ABBF01-7E7C-4A68-9139-349CE958C051Q53096322-B35672C3-6620-4DED-9F42-163DAA1F3506Q53190120-6A45968F-2794-486B-821D-36F6961367D0Q53529580-4A178EB9-6B5B-4047-94CE-899C764D9BC2Q54520286-DB6E43E4-9DAC-4EFB-B13E-4E56A6713596Q55097285-8E0C1238-3D9C-49E3-A252-DEA5337576C8Q55652763-128FFCA5-F771-467F-A946-873DC759CDD5Q58587760-A1B16CFD-3FD8-4829-9FFA-0CBF57128B97Q64916191-EF960CB6-3C19-42E4-B53E-8A3B09390598Q64983282-662CE3C5-C21A-4C49-828E-2CF3D3672AC5
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Sumeet K Asrani
@ast
Sumeet K Asrani
@en
Sumeet K Asrani
@es
Sumeet K Asrani
@nl
type
label
Sumeet K Asrani
@ast
Sumeet K Asrani
@en
Sumeet K Asrani
@es
Sumeet K Asrani
@nl
prefLabel
Sumeet K Asrani
@ast
Sumeet K Asrani
@en
Sumeet K Asrani
@es
Sumeet K Asrani
@nl
P106
P1153
35104261000
P31
P496
0000-0001-9174-5670